<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03370380</url>
  </required_header>
  <id_info>
    <org_study_id>AMD-PEA 14</org_study_id>
    <nct_id>NCT03370380</nct_id>
  </id_info>
  <brief_title>Aflibercept in Patients With Pigment Epithelial Detachments (PED)</brief_title>
  <official_title>Intravitreal Aflibercept in Patients With Retinal Pigment Epithelial Detachment (PED) Secondary to Age Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uncontrolled single site non randomized non interventional study to determine the safety and
      efficacy of intravitreal injections of Aflibercept in patients with recent vision loss due to
      retinal pigment epithelial detachment secondary to AMD
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retention and improvement of visual acuity</measure>
    <time_frame>Screening until 1 month after last injection within study eye (Month 12)</time_frame>
    <description>Visual acuity after treatment completion compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height of Pigment Epithel Detachment</measure>
    <time_frame>Screening until 1 month after last injection within study eye (Month 12)</time_frame>
    <description>The height of PED after treatment completion compared to baseline</description>
  </primary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Pigment Epithelial Detachment</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Patients are treated according to authorization of Aflibercept</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In total 20 eyes/patients are treated and observed after inclusion diagnosis and informed
        consent over a period about 1 year.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with vascular PED due to AMD

          -  Male or female patients with the age &gt; 50 years

          -  Angiographic and via OCT ensured PED ≥ 200 µm in the eye for treatment

          -  Written informed consent

          -  Best corrected visual acuity (ETDRS-Visus): 24 - 73 letters within

        Exclusion Criteria:

          -  Patients that do not fulfill the a. m. inclusion criteria

          -  Patients which have been treated with steroids or with verteporfin via photodynamic
             therapy or focal lasercoagulation treatment until 3 months before,

          -  Anti VEGF therapy until 1 month before screening

          -  Patients with other retinal vascular diseases including diabetic rethinopathia or
             retinal vein occlusion

          -  Other ocular operative procedurs 3 months before Screening

          -  Anamnesis of non controlled glaucoma

          -  Active or intraocular Inflammation or Inflammation of ocular adnexa

          -  Subfoveal fibrosis within study eye

          -  Larger surgical interventions 1 month before Screening

          -  Anamnesis of serious cardiovascular diseases or stroke 6 months before srceening

          -  Allergy of components of the study medication

          -  Patients which might be not compliant

          -  Patients participating at another clinical trial at the same time

          -  Pregnancy, breastfeeding, women in child-bearing years without using a safe
             contraception method

          -  Chronical alcohol- or drug abuse within the last year

          -  lack of capacity and/or knowledge of German language

          -  Neurologic disease i. e. multiple sclerosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Christoph Clemens, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dissociative Disorders</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

